EUVIMEDEUVIMED entdecken
Crossref

TCA Cycle Intermediate Mitigates Di(2‐ethylhexyl) Phthalate‐Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis

Yue Jiang iD, Fang Xie, Xutao Ling, Jiayi Zhang, Yun Yu, Qianqian Huang, Lun Zhang, Lu Ye, Wenkang Tao, Mengzhen Hou, Cheng Zhang, Jianqing Wang

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Yue Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Diethylhexyl Phthalate, NF-E2-Related Factor 2, Citric Acid Cycle, Dimethyl Fumarate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, University Young and Middle-aged Teacher Training Project from the Educational Commission of Anhui Province, Health Research Project of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a commonly used phthalate compound, di(2‐ethylhexyl) phthalate (DEHP) has been shown to disrupt the tricarboxylic acid (TCA) cycle and aggravate tissue damage. However, whether the TCA cycle is involved in cholestatic liver injury (CLI) induced by DEHP and the protective effect of dimethyl fumarate (DMF), which is used to supplement TCA intermediate metabolites, remained unclear. Here, mice were randomized into five groups ( n = 6/group): (1) Control, (2) DEHP (200 mg/kg/day), (3) DMF (100 mg/kg/day), (4) DEHP + DMF (30 mg/kg/day) and (5) DEHP + DMF (100 mg/kg/day). Our data demonstrated that DEHP exposure upregulated total bile acid (TBA) levels and broke the TCA cycle, resulting in reduced fumaric acid and malic acid. However, we further supplemented fumaric acid with DMF and found that DMF effectively reversed the high levels of TBA, alkaline phosphatase (ALP) and glutamyl transpeptidase (GGT) induced by DEHP in mice. Meanwhile, pathological results in the liver showed that DMF improved bile duct cell damage, inflammatory cell infiltration, collagen deposition and necrosis caused by DEHP. In addition, we found that DEHP elevated the level of interleukin (IL)‐1β, IL‐6, TNF‐α and MDA and decreased the level of SOD in the mouse liver, which was effectively reversed by DMF treatment. Besides, DMF upregulated the expression of Nrf2 and NQO1 in the liver of DEHP‐exposed mice. For in vitro validation, AML‐12 cells were treated with (1) Control, (2) DEHP (250 μM), (3) DEHP + DMF (10 μM), (4) DEHP + DMF (25 μM) and (5) DEHP + DMF (50 μM). DEHP exposure increased the expression of IL‐1β, IL‐6 and TNF‐α, which was mitigated by DMF, while ML385, an Nrf2 inhibitor, could counteract the anti‐inflammatory effects of DMF. These findings indicate that DEHP broke the TCA cycle of the mouse liver, and DMF supplementation protects against DEHP‐induced CLI by activating the Nrf2/NQO1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diethylhexyl PhthalateNF-E2-Related Factor 2Citric Acid CycleDimethyl FumarateChemical and Drug Induced Liver InjuryNAD(P)H Dehydrogenase (Quinone)CholestasisAnimalsMiceSignal TransductionMaleLiverDisease Models, Animal

Stichwörter der Autor:innen

TCA cyclecholestasis liver injurydi(2‐ethylhexyl) phthalatedimethyl fumarateinflammation

Substanzen

Diethylhexyl PhthalateNF-E2-Related Factor 2Nfe2l2 protein, mouseDimethyl FumarateNAD(P)H Dehydrogenase (Quinone)Nqo1 protein, mouse

Autor:innen und Institutionen

  • School of Pharmacy, Anhui Medical University, Hefei, China.
  • Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Anhui Public Health Clinical Center, Hefei, China.
  • Department of Toxicology, Anhui Medical University, Hefei, China.
  • Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, China.
  • MOE Key Laboratory of Population Health Across Life Cycle, Hefei, China.

ORCID-Profile: Yue Jiang

Förderung

  • National Natural Science Foundation of China
  • University Young and Middle-aged Teacher Training Project from the Educational Commission of Anhui Province
  • Health Research Project of Anhui Province
  • Anhui Public Health Clinical Center
  • First Affiliated Hospital of Anhui Medical University North Area Scientific Research Cultivation Fund Project
  • Anhui Medical University Scientific Research Fund

Zitieren

APA

Jiang, Y., Xie, F., Ling, X., Zhang, J., Yu, Y., Huang, Q., Zhang, L., Ye, L., Tao, W., Hou, M., Zhang, C., & Wang, J. (2025). TCA Cycle Intermediate Mitigates Di(2‐ethylhexyl) Phthalate‐Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70047

Vancouver

Jiang Y, Xie F, Ling X, Zhang J, Yu Y, Huang Q, et al. TCA Cycle Intermediate Mitigates Di(2‐ethylhexyl) Phthalate‐Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70047

BibTeX
@article{Jiang2025,
  author = {Jiang, Yue and Xie, Fang and Ling, Xutao and Zhang, Jiayi and Yu, Yun and Huang, Qianqian and Zhang, Lun and Ye, Lu and Tao, Wenkang and Hou, Mengzhen and Zhang, Cheng and Wang, Jianqing},
  title = {TCA Cycle Intermediate Mitigates Di(2‐ethylhexyl) Phthalate‐Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70047}
}
Kostenlos starten →